Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia

Atherosclerosis

Volumn 222, Issue 2, 2012, Pages 449-455

  Solanas Barca, María ^a   de Castro Orós, Isabel ^a,b   Mateo Gallego, Rocío ^a   Cofán, Montserrat ^c,d   Plana, Nuria ^e,f   Puzo, José ^g   Burillo, Elena ^a   Martín Fuentes, Paula ^a   Ros, Emilio ^c,d   Masana, Luis ^e,f   Pocoví, Miguel ^b   Civeira, Fernando ^a   Cenarro, Ana ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d Instituto de Salud Carlos III   (Spain)

^e HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g HOSPITAL SAN JORGE   (Spain)

Author keywords

Apolipoprotein E; Familial combined hyperlipidemia; Familial dysbetalipoproteinemia; Genetic defects

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ARGININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEUCINE; SERINE; TRIACYLGLYCEROL;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FAMILIAL HYPERLIPEMIA; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HUMAN; HYPERLIPOPROTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPAIN; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; PEDIGREE; PHENOTYPE; RECEPTORS, LDL; SPAIN;

EID: 84861347255     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.03.011     Document Type: Article

References (30)

1. Lee J.C., Lusis A.J., Pajukanta P. Familial combined hyperlipidemia: upstream transcription factor 1 and beyond. Curr Opin Lipidol 2006, 17:101-109.
2. Genest J.J., Martin-Munley S.S., McNamara J.R., et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992, 85:2025-2033.
3. Wiesbauer F., Blessberger H., Azar D., et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (<40 years of age). Eur Heart J 2009, 30:1073-1079.
4. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973, 52:1544-1568.
5. Horswell S.D., Ringham H.E., Shoulders C.C. New technologies for delineating and characterizing the lipid exome: prospects for understanding familial combined hyperlipidemia. J Lipid Res 2009, 50:S370-S375.
6. Hopkins P.N., Heiss G., Ellison R.C., et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute family heart study. Circulation 2003, 108:519-523.
7. Civeira F., Jarauta E., Cenarro A., et al. Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting. J Am Coll Cardiol 2008, 52:1546-1553.
8. Mahley R.W., Rall S.C. Type III hiperlipoproteinemia (Dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. The metabolic and molecular bases of inherited disease 2001, 2835-2862. McGrawn Hill, New York. 8th ed. C.R. Scriver, A.L. Beaudet, D. Valle, W.S. Sly (Eds.).
9. Ayyobi A.F., McGladdery S.H., McNeely M.J., Austin M.A., Motulsky A.G., Brunzell J.D. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2003, 23:1289-1294.
10. de Graaf J., van der Vleuten G.M., ter Avest E., Dallinga-Thie G.M., Stalenhoef A.F. High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia. J Clin Endocrinol Metab 2007, 92:1269-1275.
11. Gaddi A., Cicero A.F., Odoo F.O., Poli A.A., Paoletti R. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manage 2007, 3:877-886. Atherosclerosis and Metabolic Diseases Study Group.
12. Blom D.J., O'Neill F.H., Marais A.D. Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations. Clin Chem 2005, 51:904-907.
13. Gómez-Gerique J.A., Gutiérrez-Fuentes J.A., Montoya M.T., et al. Lipid profile of the Spanish population: the DRECE (diet and risk of cardiovascular disease in Spain) study. DRECE study group. Med Clin (Barc) 1999, 113:730-735.
14. Jarauta E., Mateo-Gallego R., Gilabert R., et al. Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia. Nutr Metab Cardiovasc Dis 2010, December, 31 [Epub ahead of print].
15. Tejedor D., Castillo S., Mozas P., et al. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 2005, 51:1137-1144.
16. Houlston R., Lewis B., Humphries S.E. Polymorphisms of the apolipoprotein B and E genes and their possible roles in familial and non-familial combined hyperlipidaemia. Dis Markers 1991, 9:319-325.
17. Bredie S.J., Vogelaar J.M., Demacker P.N., Stalenhoef A.F. Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia. Atherosclerosis 1996, 126:313-324.
18. Pei W.D., Zhang Y.H., Sun Y.H., et al. Apolipoprotein E polymorphism influences lipid phenotypes in Chinese families with familial combined hyperlipidemia. Circ J 2006, 70:1606-1610.
19. Sing C.F., Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985, 37:268-285.
20. Bennet A.M., Di Angelantonio E., Ye Z., et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007, 298:1300-1311.
21. Huang Y. Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. Curr Opin Lipidol 2010, 21:337-345.
22. Davignon J., Gregg R.E., Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988, 8:1-21.
23. Pocovi M., Cenarro A., Civeira F., et al. Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136→Ser) variant in multigenerational pedigree studies. Atherosclerosis 1996, 122:33-46.
24. Wardell M.R., Brennan S.O., Janus E.D., Fraser R., Carrell R.W. Apolipoprotein E2-Christchurch (136 Arg→Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. J Clin Invest 1987, 80:483-490.
25. Nguyen T.T., Kruckeberg K.E., O'Brien J.F., et al. Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149Leu)]. J Clin Endocrinol Metab 2000, 85:4354-4358.
26. Faivre L., Saugier-Veber P., Pais de Barros J.P., et al. Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation. Eur J Hum Genet 2005, 13:1186-1191.
27. Lalazar A., Weisgraber K.H., Rall S.C., et al. Site-specific mutagenesis of human apolipoprotein E. J Biol Chem 1988, 263:3542-3545.
28. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005, 112:2735-2752.
29. Solanas-Barca M., Mateo-Gallego R., Calmarza P., et al. Mutations in HFE causing hemochromatosis are associated with primary hypertriglyceridemia. J Clin Endocrinol Metab 2009, 94:4391-4397.
30. Goldberg A.C., Hopkins P.N., Toth P.P., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011, 5:133-140.